

3 April 2023

## Oesophageal and Gastric Cancer

**Q1. How many patients were treated in the past 3 months for gastric and gastro-oesophageal junction cancer (any stage) with:**

- CAPOX (Capecitabine with Oxaliplatin) <5
- FOLFOX (Folinic acid, Fluorouracil and Oxaliplatin) <5
- Lonsurf (Trifluridine - tipiracil) <5
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 12
- Any other systemic anti-cancer therapy
- CarboX with XRT (Oesophageal) <5
- Cisplatin & Etoposide (Oesophageal) <5
- Cisplatin/Etoposide (Gastric) <5
- CX + XRT (Oesophageal) 6
- CX 60/625 & Trazimera (OG) 6
- CX 60/625 (Gastric) <5
- CX 60/625 (Oesophageal) <5
- CX 80/1000 & Trazimera (OG) <5
- CX 80/1000 (Oesophageal) <5
- Docetaxel (Gastric) <5
- Docetaxel (Oesophageal) <5
- EOX (Oesophageal) <5
- Etoposide&Carbo(Oral Etop D2&3)(Oesophageal) <5
- FLOT (Gastric) 37
- IMDG (FOLFIRI) (Gastric) <5
- IMDG (FOLFIRI) (Oesophageal) 5
- Nivolumab 240mg (Oesophageal) <5
- Nivolumab 480mg (Oesophageal) <5
- Nivolumab MSI-H 240mg (Gastric) <5
- Nivolumab MSI-H 480mg (Gastric) <5
- Nivolumab MSI-H 480mg (Oesophageal) <5
- OX 80/375 & Trazimera (OG) 5
- OX 80/375 (Oesophagogastric) 15
- Weekly Paclitaxel & Carboplatin + XRT (Oesophageal) <5
- Palliative care only – not recorded

**3 April 2023**

**Q2. How many patients were treated in the past 3 months for Oesophageal cancer (any stage) with:**

- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine) OMDG-<5, OX-20
- Nivolumab monotherapy 9
- Nivolumab and Ipilimumab <5
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) <5
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine) 12
- Any other systemic anti-cancer therapy
- CarboX with XRT (Oesophageal) <5
- Cisplatin & Etoposide (Oesophageal) <5
- CX + XRT (Oesophageal) 6
- CX 60/625 & Trazimera (OG) 6
- CX 60/625 (Oesophageal) <5
- CX 80/1000 & Trazimera (OG) <5
- CX 80/1000 (Oesophageal) <5
- Docetaxel (Gastric) <5
- Docetaxel (Oesophageal) <5
- EOX (Oesophageal) <5
- Etoposide&Carbo(Oral Etop D2&3)(Oesophageal) <5
- IMDG (FOLFIRI) (Oesophageal) 5
- Weekly Paclitaxel & Carboplatin + XRT (Oesophageal) <5
- Palliative care only – not recorded

**Q3. How many patients were treated in the past 3 months for advanced/metastatic oesophageal cancer ONLY with?**

- Platinum and Fluoropyrimidene based combination treatments (Cisplatin or Oxaliplatin with 5-Fluorouracil or Capecitabine)
- Nivolumab monotherapy
- Nivolumab and Ipilimumab
- Nivolumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Pembrolizumab in combination with Platinum (Cisplatin or Oxaliplatin) and Fluoropyrimidine (5-Fluorouracil or Capecitabine)
- Any other systemic anti-cancer therapy
- Palliative care only

Not recorded

**3 April 2023**

**Q4. Does your trust participate in any clinical trials for gastric cancer? If so, please provide the name of each trial and the number of patients taking part.**

See below

**Q5. Does your trust participate in any clinical trials for oesophageal cancer? If so, please provide the name of each trial and the number of patients taking part.**

See below

3 April 2023

Studies open to recruitment				
Title acronym	Full Title	Date Study Opened	Planned recruitment end date	TOTAL study recruitment
OCCAMS	Oesophageal Cancer Clinical and Molecular Stratification Study (OCCAMS) - A Multi-Centre study to determine predictive and prognostic biomarkers and therapeutic targets for oesophageal and junctional adenocarcinoma including whole genome sequencing	15/01/2015	Currently suspended	132
ADD-ASPIRIN (with GI cohort)	A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non metastatic solid tumours.	01/11/2017	Q2 2025	6 (GI cohort)
SCOPE 2	A randomised Phase II/III trial to study radiotherapy dose escalation in patients with oesophageal cancer treated with definitive chemo-radiation with an embedded Phase II trial for patients with a poor early response using positron emission tomography (PET)	21/01/2019	31/05/2023	10
PLATFORM	Planning treatment for <u>oesophago-gastric</u> cancer: a randomised maintenance therapy trial (PLATFORM Trial)	06/06/2019	31/03/2025	<5 recruited <5 randomised
ICHOR	Investigation of Circulating Haematological Biomarkers in Cancer	01/08/2019	31/05/2025	17
REGAL	Capturing <u>trastuzumab REsistance</u> in Gastroesophageal Adenocarcinoma by Liquid biopsy	15/06/2022	Closed 21/07/2022	<5

3 April 2023

Studies in set-up or under consideration		
Title acronym	Full Title	
PROTEAN	Proteomic Profiling of Oesophageal and Gastroesophageal Junction Adenocarcinoma <u>Neoantigens</u>	Study in-set
DECIPHER	A single arm phase II trial of <u>trastuzumab deruxtecan</u> in patients with <u>gastroesophageal adenocarcinoma</u> cancer who are <u>ctDNA</u> and HER2 positive.	Study undergoing feasibility assessment
DESTINY-04	A Phase 3, <u>Multicenter</u> , 2-Arm Randomized, Open-Label Study of <u>Trastuzumab Deruxtecan</u> in Subjects with HER2-Positive Metastatic and/or <u>Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma</u> Subjects who have Progressed on or After a <u>Trastuzumab-Containing Regimen</u> ((DESTINY-Gastric04)	Study undergoing feasibility assessment